Literature DB >> 28741380

Genetic Modification of T Cells with Chimeric Antigen Receptors: A Laboratory Manual.

Viktória Golumba-Nagy1, Johannes Kuehle1, Hinrich Abken1.   

Abstract

Redirected T cells genetically modified with a chimeric antigen receptor (CAR) have induced spectacular remissions of refractory leukemia/lymphoma in early phase trials, attracting interest to use CAR T cells in a variety of other applications including solid cancer and nonmalignant diseases. However, extensive preclinical explorations demand highly effective and robust procedures for the genetic modification of blood T cells; the same applies for engineering with a recombinant T cell receptor. We present laboratory procedures in a step-by-step protocol to engineer human and mouse T cells with a CAR by γ-retro- or lentiviral transduction for further preclinical testing.

Entities:  

Keywords:  CAR; T cell; chimeric antigen receptor; lentivirus; transduction; γ-retrovirus

Mesh：

Substances：

Year:  2017        PMID： 28741380     DOI： 10.1089/hgtb.2017.083

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN： 1946-6536            Impact factor:   2.396


  9 in total

Review 1.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

2.  CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.

Authors:  Viktória Golumba-Nagy; Johannes Kuehle; Andreas A Hombach; Hinrich Abken
Journal:  Mol Ther       Date:  2018-07-10       Impact factor: 11.454

3.  Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2019-06-19       Impact factor: 11.454

4.  IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors.

Authors:  Andreas Hombach; Markus Barden; Lisa Hannappel; Markus Chmielewski; Gunter Rappl; Agapios Sachinidis; Hinrich Abken
Journal:  Mol Ther       Date:  2021-10-19       Impact factor: 11.454

5.  Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir.

Authors:  Lea Patasic; Janna Seifried; Valerie Bezler; Marcell Kaljanac; Irene C Schneider; Heike Schmitz; Christiane Tondera; Jessica Hartmann; Andreas Hombach; Christian J Buchholz; Hinrich Abken; Renate König; Klaus Cichutek
Journal:  Med Microbiol Immunol       Date:  2020-09-12       Impact factor: 3.402

Review 6.  Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Authors:  Ciprian Tomuleasa; Shigeo Fuji; Cristian Berce; Anca Onaciu; Sergiu Chira; Bobe Petrushev; Wilhelm-Thomas Micu; Vlad Moisoiu; Ciprian Osan; Catalin Constantinescu; Sergiu Pasca; Ancuta Jurj; Laura Pop; Ioana Berindan-Neagoe; Delia Dima; Shigehisa Kitano
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 7.  Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.

Authors:  Yan-Bei Ren; Shang-Jun Sun; Shuang-Yin Han
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

8.  PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.

Authors:  Jamal Alzubi; Viviane Dettmer-Monaco; Johannes Kuehle; Niko Thorausch; Maximilian Seidl; Sanaz Taromi; Wolfgang Schamel; Robert Zeiser; Hinrich Abken; Toni Cathomen; Philipp Wolf
Journal:  Mol Ther Oncolytics       Date:  2020-06-24       Impact factor: 7.200

9.  IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells.

Authors:  Andreas A Hombach; Ulf Geumann; Christine Günther; Felix G Hermann; Hinrich Abken
Journal:  Cells       Date:  2020-04-03       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.